<DOC>
	<DOCNO>NCT02460016</DOCNO>
	<brief_summary>This study ass safety , tolerability , pharmacokinetics ( PK ) anti-viral effect single dose AK0529 infant hospitalize respiratory syncytial virus ( RSV ) .</brief_summary>
	<brief_title>A Study AK0529 Infants Hospitalized With RSV</brief_title>
	<detailed_description>This open-label Phase 1b study evaluate safety , tolerability , pharmacodynamics Pharmacokinetics AK0529 hospitalize RSV infect infant age 1 24 month .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>Male female subject race ethnicity age adjust prematurity ≥1 month ≤24 month . Diagnosis RSV infection virological . Subject must weigh &gt; 3 kg screening . Must provide write informed consent subject participate . For patient age &lt; 12 month , occipitofrontal head circumference ( OFHC ) within normal range age gender . The subject take , currently take require restrict medication . Subject know HIVpositive ( mother , potential subject child age &lt; 6 month ) . Participation investigational drug device study within 30 day prior date screening . Requires vasopressor inotropic support time enrollment . Concurrent gastrointestinal condition could , opinion investigator , prejudice absorption Investigational Medicinal Product ( e.g . protract vomiting , malabsorption syndrome , history necrotising enterocolitis consequent short gut syndrome ) . Bronchopulmonary dysplasia chronic lung disease require assist ventilation time enrollment . Diminished ventilatory reserve risk hypercapnia ( e.g . pulmonary hypoplasia , sequestration syndrome , cystadenomatoid malformation , history surgery diaphragmatic hernia ) . Left right shunt merit corrective therapy .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>